Primary insider notification – Allocation overview
(Oslo, Norway, 5 October 2016) Reference is made to the announcement on 14 September 2016 regarding the Rights Offering in Bionor Pharma ASA (the “Company”) and the announcement on 4 October 2016 regarding the final result of the Rights Offering.
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
After yesterday’s allocation of shares in the Rights Offering, the primary insiders who were allocated shares in the Rights Offering holds the following interests in the Company:
|Name||Position||Allocation of shares in the Rights issue||Warrants||Total number of shares after Rights Issue|
|Per S. Thoresen through Bekkestua Venture AS||Board member||1,183,690||0||1,183,690|
|Unni Hjelmaas through Hjelmaas AS||Acting CEO||473,476||0||473,476|
Cecilie Grue through Grue Invest AS
|Director of legal affairs||195,499||105,600||301,099|
|Gunnar Flåten||Director of Finance||800,000||0||1,617,500|
|Maja A. Sommerfelt||VP, Director of Research & External Innovation||591,106||0||910,393|
The subscription price for the shares in the Rights Offering was NOK 0.10 per share.
Link to the announcement in pdf